EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Combined low muscle mass and body mass index for prognosis in esophageal squamous cell carcinoma patients receiving immunochemoradiotherapy

Ling Xiao, Lin-Jie Li, Jia-Hua Lyu, Shi-Chuan Zhang, Long Liang

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.123631 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Locally advanced esophageal squamous cell carcinoma is widely treated with curative immunochemoradiotherapy. While low muscle mass (LMM) and body mass index (BMI) correlate with cancer prognosis, their joint prognostic role in this patient group is poorly defined. AIM To investigate the prognostic value of combined LMM and BMI stratification in this patient population, and evaluate the impact of body composition on survival. METHODS This single-center retrospective cohort study included 105 patients. Skeletal muscle index was calculated from computed tomography images at the L3 vertebral level, and LMM was defined using Asian-specific skeletal muscle index cutoff values. Restricted cubic spline analysis identified the optimal BMI cutoff. Survival was analyzed using the Kaplan-Meier method, and independent prognostic factors were identified using multivariable Cox regression. RESULTS Patients with LMM had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without LMM (all P < 0.001). BMI-stratified analysis showed significant heterogeneity in the prognostic value of LMM. LMM did not distinguish survival in patients with BMI < 22.0 kg/m2 but significantly predicted poorer PFS and OS in those with BMI ≥ 22.0 kg/m2 (both P < 0.001). Although patients with both LMM and low BMI had the poorest survival, multivariable analysis identified normal muscle mass combined with high BMI as an independent protective factor for PFS (hazard ratio = 0.316, 95% confidence interval: 0.147-0.678; P = 0.003) and OS (hazard ratio = 0.265, 95% confidence interval: 0.119-0.588; P = 0.001). CONCLUSION Among patients with esophageal squamous cell carcinoma receiving immunochemoradiotherapy, LMM has greater prognostic value in those with a high BMI. Combined assessment of LMM and BMI improves risk stratification and may facilitate individualized treatment planning.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →